Catyalyst Pharma (CPRX) Tops Q2 EPS by 2c

Catyalyst Pharma (NASDAQ: CPRX) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained